Source: Annual Congress 2002 - COPD - Drug therapy 2
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. D. Spencer, J. Zhu, D. Izard (Greenford, United Kingdom; Collegeville, United States Of America). The direct costs of exacerbations in COPD and the effect of cilomilast treatment. Eur Respir J 2002; 20: Suppl. 38, 1588

Member's Comments

No comment yet.

Related content which might interest you: The effect of tiotropium in the treatment of patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 The costs of exacerbations in COPD Source: Eur Respir J 2001; 18: Suppl. 33, 273s Year: 2001 The effect of tiotropium in COPD complicated with asthma Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Effect of roflumilast on hospitalizations in COPD patients Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 526s Year: 2006 Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Budesonide/formoterol added to tiotropium improves exacerbations and exacerbation-related antibiotic use in patients with COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma Source: Eur Respir J, 57 (2) 2002436; 10.1183/13993003.02436-2020 Year: 2021 Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Impact of roflumilast treatment on the rate and duration of exacerbations and overall steroid load in patients with COPD Source: Annual Congress 2011 - COPD management Year: 2011 The effect of roflumilast in addition to LABA/LAMA/ICS treatment in COPD patients Source: Eur Respir J 2014; 44: 527-529 Year: 2014 QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Evaluation of costs of inhospital treatment of COPD exacerbations Source: Eur Respir J 2004; 24: Suppl. 48, 64s Year: 2004 Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Formoterol given either alone or together with tiotropium, reduces the rate of exacerbations in stable COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 430s Year: 2006 Pharmacologic treatment of exacerbations of COPD Source: International Congress 2016 – Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society (ERS/ATS) guideline Year: 2016 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015